NeoGenomics, Inc.

NxGenHealthcare & BiotechnologyUnited States

71% match

NxGen MDx is a privately held medical consulting and genetic screening company headquartered in Grand Rapids, Michigan, offering specialized laboratory and diagnostic testing services.

CANCER GENETICS, INCBiotechnologyUnited States

70% matchPrivate

Cancer Genetics, Inc. is a biotechnology company headquartered in Rutherford, New Jersey, with operational history including facilities in Los Angeles, California. The company provides specialized oncology-focused diagnostic products, genomic services, and biomarker testing.

Foundation MedicineBiotechGermany

69% match

Foundation Medicine, Inc. is an American company based in Boston, Massachusetts, which develops, manufactures, and sells genomic profiling assays based on next-generation sequencing technology for solid tumors, hematologic malignancies, and sarcomas.

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

Invitae CorporationBiotechUnited States

68% matchPrivate

Invitae Corp. is a biotechnology company specializing in genetic testing and laboratory services. The firm has operated with a significant operational footprint and experienced corporate acquisitions within the healthcare market.

Nexome Genomics Inc.BiotechnologyUnited States

67% matchPrivate

Nexome Genomics provides cloud-based, integrated analytics solutions that process next-generation sequencing data for healthcare institutions. The company enables hospitals, medical centers, and physician offices to generate on-demand diagnostic and prognostic reports for precision medicine.